Table 4.

Neurologist network: demographic and clinical data pertaining to seven GBS patients with influenza immunisations during the 42-day period preceding clinical onset

Patient ref. no., sex, age	Vaccination date and type (a)	Co-morbidity or clinical antecedent in 30 days prior to onset	Symptom onset (b)	(a-b) Interval in weeks	Functional level at one week	Treatment	Clinical confirmation on the basis of
1 Female 53	2 Oct 2009	Motor neurone disease	13 Oct 2009	1–2	Walking	Not treated	Clinical symptoms/exam.
	2009-TIV						Cerebrospinal fluid (CSF) tests
							Electrophysiology lab.
							Other causes excluded
2 Male 68	27 Oct 2009	Heart disease.	22 Nov 2009	3–4	Bed-bound	IVGG	Electrophysiology lab.
	2009-TIV	Sleep apnea. High blood pressure. Bronchopulmonary infection					Other causes excluded
3 Male 34	20 Oct 2009	Syphilis seropositive	30 Nov 2009	5–6	Walking	IVGG	Clinical symptoms/exam.
	2009-TIV						CSF tests
							Electrophysiology lab.
							Other causes excluded
4 Male 70	28 Sept 2009	Motor neurone disease	10 Oct 2009	1–2	Bed-bound	IVGG	Clinical symptoms/exam
	2009-TIV						CSF tests
							Electrophysiology lab.
							Other causes excluded
5 Male 77	18 Oct 2010	-	1 Nov 2010	2	Bed-bound	IVGG	Clinical symptoms/exam.
	2010–2011-TIVa						Electrophysiology lab. Other causes excluded
6 Female 78	5 Jan 2011	-	15 Jan 2011	1–2	Able to walk with support	IVGG	Clinical symptoms/exam.
	2010–2011-TIV						CSF tests
							Electrophysiology lab. Other causes excluded
7 Male 82	27 Oct 2011	High blood pressure	23 Nov 2011	4	Bed-bound	IVGG Mechanical Ventilation	Clinical symptoms/exam.
	2010–2011-TIVa	DM					CSF tests
		Atrial fibrillation					Electrophysiology lab. Other causes excluded

GBS Guillain-Barré syndrome, DM diabetes mellitus type 2, TIV seasonal trivalent influenza vaccine, IVGG intravenous gammaglobulin

^aReceived the vaccine Chiromas® (Novartis), adjuvanted with MF59C.1